EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies

Lei Xia, Yan Wu, Yanan Ren, Zhen Wang, Nina Zhou, Wenyuan Zhou, Lixin Zhou, Ling Jia, Chengxue He, Xiangxi Meng, Hua Zhu, Zhi Yang

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci186388 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Lei Xia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation…. Hauptthemen laut MEDLINE: B7 Antigens, Whole Body Imaging, Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Young Elite Scientists Sponsorship Program by CAST.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND B7H3, also known as CD276, is notably overexpressed in various malignant tumor cells in humans, with extremely high expression rates. The development of a radiotracer that targets B7H3 may provide a universal tumor-specific imaging agent and allow the noninvasive assessment of the whole-body distribution of B7H3-expressing lesions. METHODS We enhanced and optimized the structure of an affibody (ABY) that targets B7H3 to create the radiolabeled radiotracer [ 68 Ga]Ga-B7H3-BCH, and then, we conducted both foundational experiments and clinical translational studies. RESULTS [ 68 Ga]Ga-B7H3-BCH exhibited high affinity (equilibrium dissociation constant [K D ] = 4.5 nM), and it was taken up in large amounts by B7H3-transfected cells (A549 CD276 and H1975 CD276 cells); these phenomena were inhibited by unlabeled precursors. Moreover, PET imaging of multiple xenograft models revealed extensive [ 68 Ga]Ga-B7H3-BCH uptake by tumors. In a clinical study including 20 patients with malignant tumors, the [ 68 Ga]Ga-B7H3-BCH signal aggregated in both primary and metastatic lesions, surpassing fluorine-18 fluorodeoxyglucose ( 18 F-FDG) in overall diagnostic efficacy for tumors (85.0% vs. 81.7%), including differentiated hepatocellular and metastatic gastric cancers. A strong correlation between B7H3 expression and [ 68 Ga]Ga-B7H3-BCH uptake in tumors was observed, and B7H3 expression was detected with 84.38% sensitivity and 100% specificity when a maximum standardized uptake value (SUVmax) of 3.85 was set as the cutoff value. Additionally, B7H3-specific PET imaging is expected to predict B7H3 expression levels in tumor cells, intratumoral stroma, and peritumoral tissues. CONCLUSION In summary, [ 68 Ga]Ga-B7H3-BCH has potential for the noninvasive identification of B7H3 expression in systemic lesions in patients with malignant tumors. This agent has prospects for improving pretreatment evaluation, predicting therapeutic responses, and monitoring resistance to therapy in patients with malignancies. TRIAL REGISTRATION ClinicalTrials.gov NCT06454955. FUNDING This research was financially supported by the Natural Science Foundation of Beijing Municipality (no. 7242266), the National Natural Science Foundation of China (no. 82202201), and the Young Elite Scientists Sponsorship Program by China Association for Science and Technology (CAST) (no. YESS20220230).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7 AntigensWhole Body ImagingNeoplasmsPositron-Emission TomographyRadiopharmaceuticalsHumansAnimalsMiceFemaleCell Line, TumorMaleGallium RadioisotopesMiddle Aged

Stichwörter der Autor:innen

CancerClinical trialsDevelopmentMolecular diagnosisOncology

Substanzen

B7 AntigensCD276 protein, humanGallium RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluat…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China.
  • Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Hepato-Pancreato-Biliary Surgery, Sarcoma Center, Peking University Cancer Hospital and Institute, Beijing, Chi…

Förderung

  • the Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China
  • Young Elite Scientists Sponsorship Program by CAST

Zitieren

APA

Xia, L., Wu, Y., Ren, Y., Wang, Z., Zhou, N., Zhou, W., Zhou, L., Jia, L., He, C., Meng, X., Zhu, H., & Yang, Z. (2025). A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies. Journal of Clinical Investigation. https://doi.org/10.1172/jci186388

Vancouver

Xia L, Wu Y, Ren Y, Wang Z, Zhou N, Zhou W, et al. A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies. Journal of Clinical Investigation. 2025. doi:10.1172/jci186388

BibTeX
@article{Xia2025,
  author = {Xia, Lei and Wu, Yan and Ren, Yanan and Wang, Zhen and Zhou, Nina and Zhou, Wenyuan and Zhou, Lixin and Jia, Ling and He, Chengxue and Meng, Xiangxi and Zhu, Hua and Yang, Zhi},
  title = {A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci186388}
}
Kostenlos starten →